What's Happening?
Morgan Lewis litigation partner Evan Jacobs and of counsel Maureen Barber are scheduled to speak at the American Conference Institute’s (ACI’s) 31st Annual Conference on Drug and Medical Device Litigation in December 2026. Evan Jacobs will participate
in a panel titled 'Artificial Intelligence Litigation Showcase: AI and Accompanying Tools That are Rapidly Transforming the Life Sciences Product Liability Sector.' This panel will explore how AI is changing litigation strategies, case management, and trial preparation in drug and medical device product liability cases. Discussions will cover emerging AI tools for document review, motion development, oral argument preparation, and trial demonstrations, as well as methods to enhance litigation efficiency. The panel will also address risks associated with AI-assisted legal representation, privilege concerns, judicial oversight, disclosure requirements, and ethical considerations for litigators using AI. Maureen Barber will speak on 'One-Year Update on Rule 16.1: Bench and Litigant Approaches to the Different Stages of MDL Matters,' discussing the impact of Federal Rule of Civil Procedure 16.1, which became effective in December 2025, on case management and judicial discretion in multidistrict litigation (MDL) proceedings.
Why It's Important?
The discussions at the ACI conference highlight critical developments impacting the U.S. legal landscape, particularly in the life sciences sector. The integration of AI into litigation strategies signifies a major shift in how legal professionals approach complex cases, potentially leading to increased efficiency and new challenges related to ethics and compliance. For drug and medical device companies, understanding these AI advancements is crucial for managing product liability risks and navigating legal disputes. The focus on Federal Rule of Civil Procedure 16.1 is equally significant, as it directly affects how MDLs are managed, potentially streamlining or complicating large-scale litigation involving numerous plaintiffs and defendants. The rule's impact on judicial discretion and early case management could influence the outcomes and timelines of major legal battles, affecting both corporate defendants and plaintiffs seeking redress. The evolving legal framework around AI and MDLs will shape future litigation practices and outcomes across the U.S.
What's Next?
The insights shared at the ACI conference will likely inform legal strategies and best practices for attorneys and companies involved in drug and medical device litigation. The discussions on AI's role will prompt legal departments and law firms to further evaluate and adopt AI tools, while also developing robust frameworks to address associated ethical and compliance challenges. The one-year update on Rule 16.1 will provide valuable feedback on its practical application, potentially leading to further interpretations or adjustments in how federal courts handle MDLs. This ongoing evaluation will be crucial for legal practitioners to adapt their approaches to mass tort and product liability cases. The legal community will continue to monitor judicial interpretations and litigant responses to both AI integration and the new procedural rule, shaping the future of complex litigation in the U.S.
Beyond the Headlines
The increasing reliance on AI in legal processes raises profound questions about the future of legal practice, including the balance between human expertise and technological assistance. Ethical considerations, such as data privacy, algorithmic bias, and the potential for AI to influence judicial outcomes, will become central to legal discourse. The adoption of AI could also exacerbate existing disparities in legal resources, as firms with greater technological access may gain a competitive advantage. Furthermore, the evolving nature of MDLs, influenced by rules like 16.1, reflects a broader effort to manage the complexities of modern litigation, which often involves scientific and technical evidence. These developments underscore a long-term trend towards a more technologically integrated and procedurally refined legal system, with implications for access to justice and the fundamental principles of legal representation.
